Pathophysiology of irritable bowel syndrome

The Lancet Gastroenterology and Hepatology

Volumn 1, Issue 2, 2016, Pages 133-146

  Holtmann, Gerald J ^a   Ford, Alexander C ^b,c   Talley, Nicholas J ^d,e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTIPOL; COLESTYRAMINE; EBASTINE; ELOBIXIBAT; GLUTEN; LARAZOTIDE; LUBIPROSTONE; MEXILETINE; ONDANSETRON; PRUCALOPRIDE; RAMOSETRON; RIFAXIMIN;

ACTIVE IMMUNIZATION; BILE SALT METABOLISM DISORDER; BRAIN DYSFUNCTION; CELIAC DISEASE; CELL HETEROGENEITY; DIARRHEA; DIET; DYSBIOSIS; GENE; GENETIC DISORDER; GUT BRAIN DISORDER; HUMAN; INTESTINE FLORA; INTESTINE INFECTION; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; METABOLIC DISORDER; MOOD DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCN5A GENE; SEROTONIN METABOLISM; SEROTONIN METABOLISM DISORDER; COMPLICATION; GENETIC PREDISPOSITION; INFECTION; PSYCHOLOGY; RISK FACTOR;

DIET; GASTROINTESTINAL MICROBIOME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFECTION; IRRITABLE BOWEL SYNDROME; RISK FACTORS;

EID: 84996523425     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(16)30023-1     Document Type: Review

References (135)

1. 1 Pimentel, M, Talley, NJ, Quigley, EM, Hani, A, Sharara, A, Mahachai, V, Report from the multinational irritable bowel syndrome initiative 2012. Gastroenterology 144 (2013), e1–e5.
2. 2 Lovell, RM, Ford, AC, Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10 (2012), 712–721.
3. 3 Ford, AC, Moayyedi, P, Lacy, BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 109:suppl 1 (2014), S2–26.
4. 4 Talley, NJ, Holtmann, G, Walker, MM, Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology. J Gastroenterol 50 (2015), 601–613.
5. 5 Ford, AC, Forman, D, Bailey, AG, Axon, AT, Moayyedi, P, Irritable bowel syndrome: a 10-year natural history of symptoms, and factors that influence consultation behavior. Am J Gastroenterol 103 (2008), 1229–1239.
6. 6 Peery, AF, Crockett, SD, Barritt, AS, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology 149 (2015), 1731–1741.
7. 7 Chang, JY, Locke, GR, McNally, MA, et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol 105 (2010), 822–832.
8. 8 Mikocka-Walus, A, Turnbull, D, Moulding, N, Wilson, I, Andrews, JM, Holtmann, G, Psychological comorbidity and complexity of gastrointestinal symptoms in clinically diagnosed irritable bowel syndrome patients. J Gastroenterol Hepatol 23 (2008), 1137–1143.
9. 9 Halpin, SJ, Ford, AC, Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 107 (2012), 1474–1482.
10. 10 Sainsbury, A, Sanders, DS, Ford, AC, Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis. Clin Gastroenterol Hepatol 11 (2013), 359–365.
11. 11 Slattery, SA, Niaz, O, Aziz, Q, Ford, AC, Farmer, AD, Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 42 (2015), 3–11.
12. 12 Kamp, EJ, Kane, JS, Ford, AC, Irritable bowel syndrome and microscopic colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 14 (2016), 659–668.
13. 13 Gururatsakul, M, Holloway, RH, Bellon, M, Bartholomeusz, D, Talley, NJ, Holtmann, GJ, Complicated and uncomplicated peptic ulcer disease: altered symptom response to a nutrient challenge linked to gastric motor dysfunction. Digestion 89 (2014), 239–246.
14. 14 Sullivan, MA, Cohen, S, Snape, WJ Jr, Colonic myoelectrical activity in irritable-bowel syndrome: effect of eating and anticholinergics. N Engl J Med 298 (1978), 878–883.
15. 15 Ritchie, J, Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 14 (1973), 125–132.
16. 16 Henningsen, P, Zimmermann, T, Sattel, H, Medically unexplained physical symptoms, anxiety and depression: a meta-analytic review. Psychosom Med 65 (2003), 528–533.
17. 17 Patel, P, Bercik, P, Morgan, DG, et al. Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating. Aliment Pharmacol Ther 41 (2015), 449–458.
18. 18 Tanaka, Y, Kanazawa, M, Fukudo, S, Drossman, DA, Biopsychosocial model of irritable bowel syndrome. J Neurogastroenterol Motil 17 (2011), 131–139.
19. 19 Wessely, S, Nimnuan, C, Sharpe, M, Functional somatic syndromes: one or many?. Lancet 354 (1999), 936–939.
20. 20 Koloski, NA, Jones, M, Kalantar, J, Weltman, M, Zaguirre, J, Talley, NJ, The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 61 (2012), 1284–1290.
21. 21 Jones, MP, Van Oudenhove, L, Talley, NJ, Functional gastrointestinal disorders (FGIDs) and psychological disorders: strong evidence that the link is bidirectional, but psychological distress is more likely to precede a new diagnosis of an FGID. Gastroenterology, 142(suppl 1), 2012, S570 (abstr).
22. 22 Koloski, NA, Jones, MP, Talley, NJ, Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study. Aliment Pharmacol Ther 44 (2016), 592–600.
23. 23 Sykes, MA, Blanchard, EB, Lackner, J, Keefer, L, Krasner, S, Psychopathology in irritable bowel syndrome: support for a psychophysiological model. J Behav Med 26 (2003), 361–372.
24. 24 Liebregts, T, Adam, B, Bredack, C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 132 (2007), 913–920.
25. 25 Mayer, EA, Savidge, T, Shulman, RJ, Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 146 (2014), 1500–1512.
26. 26 Young, E, Stoneham, MD, Petruckevitch, A, Barton, J, Rona, R, A population study of food intolerance. Lancet 343 (1994), 1127–1130.
27. 27 David, LA, Maurice, CF, Carmody, RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505 (2014), 559–563.
28. 28 Francis, CY, Whorwell, PJ, Bran and irritable bowel syndrome: time for reappraisal. Lancet 344 (1994), 39–40.
29. 29 Shepherd, SJ, Parker, FC, Muir, JG, Gibson, PR, Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 6 (2008), 765–771.
30. 30 Murray, K, Wilkinson-Smith, V, Hoad, C, et al. Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol 109 (2014), 110–119.
31. 31 Elli, L, Tomba, C, Branchi, F, et al. Evidence for the presence of non-celiac gluten sensitivity in patients with functional gastrointestinal symptoms: results from a multicenter randomized double-blind placebo-controlled gluten challenge. Nutrients, 8, 2016, 84.
32. 32 Coletta, M, Gates, FK, Marciani, L, et al. Effect of bread gluten content on gastrointestinal function: a crossover MRI study on healthy humans. Br J Nutr 115 (2016), 55–61.
33. 33 Vazquez-Roque, MI, Camilleri, M, Smyrk, T, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 144 (2013), 903–911.
34. 34 Saito, YA, Petersen, GM, Larson, JJ, et al. Familial aggregation of irritable bowel syndrome: a family case-control study. Am J Gastroenterol 105 (2010), 833–841.
35. 35 Lembo, A, Zaman, M, Jones, M, Talley, NJ, Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment Pharmacol Ther 25 (2007), 1343–1350.
36. 36 Locke, GR 3rd, Ackerman, MJ, Zinsmeister, AR, Thapa, P, Farrugia, G, Gastrointestinal symptoms in families of patients with an SCN5A-encoded cardiac channelopathy: evidence of an intestinal channelopathy. Am J Gastroenterol 101 (2006), 1299–1304.
37. 37 Saito, YA, Strege, PR, Tester, DJ, et al. Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy. Am J Physiol Gastrointest Liver Physiol 296 (2009), G211–G218.
38. 38 Beyder, A, Mazzone, A, Strege, PR, et al. Loss-of-function of the voltage-gated sodium channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome. Gastroenterology 146 (2014), 1659–1668.
39. 39 Swan, C, Duroudier, NP, Campbell, E, et al. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα. Gut 62 (2013), 985–994.
40. 40 Zucchelli, M, Camilleri, M, Andreasson, AN, et al. Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut 60 (2011), 1671–1677.
41. 41 Sasaki, A, Sato, N, Suzuki, N, et al. Associations between single-nucleotide polymorphisms in corticotropin-releasing hormone-related genes and irritable bowel syndrome. PLoS One, 11, 2016, e0149322.
42. 42 Wouters, MM, Lambrechts, D, Knapp, M, et al. Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. Gut 63 (2014), 1003–1011.
43. 43 Grasberger, H, Chang, L, Shih, W, et al. Identification of a functional TPH1 polymorphism associated with irritable bowel syndrome bowel habit subtypes. Am J Gastroenterol 108 (2013), 1766–1774.
44. 44 Jun, S, Kohen, R, Cain, KC, Jarrett, ME, Heitkemper, MM, Associations of tryptophan hydroxylase gene polymorphisms with irritable bowel syndrome. Neurogastroenterol Motil 23 (2011), 233–239.
45. 45 Camilleri, M, Kolar, GJ, Vazquez-Roque, MI, Carlson, P, Burton, DD, Zinsmeister, AR, Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits. Am J Physiol Gastrointest Liver Physiol 304 (2013), G553–G560.
46. 46 Wong, BS, Camilleri, M, Carlson, P, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 10 (2012), 1009–1015.
47. 47 Wong, BS, Camilleri, M, Carlson, PJ, et al. A klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology 140 (2011), 1934–1942.
48. 48 Ek, WE, Reznichenko, A, Ripke, S, et al. Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut 64 (2014), 1774–1782.
49. 49 Beaudoin, M, Goyette, P, Boucher, G, et al. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genet, 9, 2013, e1003723.
50. 50 Franke, A, McGovern, DP, Barrett, JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 42 (2010), 1118–1125.
51. 51 Czogalla, B, Schmitteckert, S, Houghton, LA, et al. A meta-analysis of immunogenetic case-control association studies in irritable bowel syndrome. Neurogastroenterol Motil 27 (2015), 717–727.
52. 52 Mahurkar, S, Polytarchou, C, Iliopoulos, D, Pothoulakis, C, Mayer, EA, Chang, L, Genome-wide DNA methylation profiling of peripheral blood mononuclear cells in irritable bowel syndrome. Neurogastroenterol Motil 28 (2016), 410–422.
53. 53 Ford, AC, Thabane, M, Collins, SM, et al. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology 138 (2010), 1727–1736.
54. 54 Marshall, JK, Thabane, M, Garg, AX, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 59 (2010), 605–611.
55. 55 Adam, B, Liebregts, T, Gschossmann, JM, et al. Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model. Pain 123 (2006), 179–186.
56. 56 Liebregts, T, Adam, B, Bertel, A, et al. Psychological stress and the severity of post-inflammatory visceral hyperalgesia. Eur J Pain 11 (2007), 216–222.
57. 57 Wouters, MM, Van Wanrooy, S, Nguyen, A, et al. Psychological comorbidity increases the risk for postinfectious IBS partly by enhanced susceptibility to develop infectious gastroenteritis. Gut 65 (2016), 1279–1288.
58. 58 Riddle, MS, Welsh, M, Porter, CK, et al. The epidemiology of irritable bowel syndrome in the US military: findings from the millennium cohort study. Am J Gastroenterol 111 (2016), 93–104.
59. 59 Walker, MM, Talley, NJ, Ingañas, L, et al. Colonic spirochetosis is associated with colonic eosinophilia and irritable bowel syndrome in a general population in Sweden. Hum Pathol 46 (2015), 277–283.
60. 60 Liebregts, T, Adam, B, Bertel, A, et al. Effect of E Coli Nissle 1917 on post-inflammatory visceral sensory function in a rat model. Neurogastroenterol Motil 17 (2005), 410–414.
61. 61 Verdú, EF, Bercík, P, Bergonzelli, GE, et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 127 (2004), 826–837.
62. 62 Jalanka-Tuovinen, J, Salojärvi, J, Salonen, A, et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 63 (2014), 1737–1745.
63. 63 Sundin, J, Rangel, I, Fuentes, S, et al. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther 41 (2015), 342–351.
64. 64 Carroll, IM, Ringel-Kulka, T, Siddle, JP, Ringel, Y, Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 24 (2012), 521–530.
65. 65 Chassard, C, Dapoigny, M, Scott, KP, et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 35 (2012), 828–838.
66. 66 Ringel-Kulka, T, Choi, CH, Temas, D, et al. Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome. Am J Gastroenterol 110 (2015), 1339–1346.
67. 67 Kim, G, Deepinder, F, Morales, W, et al. Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig Dis Sci 57 (2012), 3213–3218.
68. 68 Lin, HC, Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 292 (2004), 852–858.
69. 69 Pimentel, M, Chow, EJ, Lin, HC, Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95 (2000), 3503–3506.
70. 70 Bratten, JR, Spanier, J, Jones, MP, Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 103 (2008), 958–963.
71. 71 Posserud, I, Stotzer, PO, Björnsson, ES, Abrahamsson, H, Simrén, M, Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56 (2007), 802–808.
72. 72 Pimentel, M, Park, S, Mirocha, J, Kane, SV, Kong, Y, The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Int Med 145 (2006), 557–563.
73. 73 Pimentel, M, Lembo, A, Chey, WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364 (2011), 22–32.
74. 74 Xu, D, Gao, J, Gillilland, M 3rd, et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 146 (2014), 484–496.
75. 75 Ford, AC, Quigley, EM, Lacy, BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 109 (2014), 1547–1561.
76. 76 Ford, AC, Talley, NJ, Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol 46 (2011), 421–431.
77. 77 Collins, SM, Is the irritable gut an inflamed gut?. Scand J Gastroenterol Suppl 192 (1992), 102–105.
78. 78 Wensaas, KA, Langeland, N, Hanevik, K, Mørch, K, Eide, GE, Rortveit, G, Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study. Gut 61 (2012), 214–219.
79. 79 Cremon, C, Stanghellini, V, Pallotti, F, et al. Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood. Gastroenterology 147 (2014), 69–77.
80. 80 Mearin, F, Perelló, A, Balboa, A, et al. Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: results 3 years after gastroenteritis. Scand J Gastroenterol 44 (2009), 1173–1185.
81. 81 Gwee, KA, Collins, SM, Read, NW, et al. Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome. Gut 52 (2003), 523–526.
82. 82 Coëffier, M, Gloro, R, Boukhettala, N, et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol 105 (2010), 1181–1188.
83. 83 Zhen, Y, Chu, C, Zhou, S, Qi, M, Shu, R, Imbalance of tumor necrosis factor-α, interleukin-8 and interleukin-10 production evokes barrier dysfunction, severe abdominal symptoms and psychological disorders in patients with irritable bowel syndrome-associated diarrhea. Mol Med Rep 12 (2015), 5239–5245.
84. 84 Ohman, L, Lindmark, AC, Isaksson, S, et al. B-cell activation in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil 21 (2009), 644–650.
85. 85 Vicario, M, González-Castro, AM, Martínez, C, et al. Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. Gut 64 (2015), 1379–1388.
86. 86 Hughes, PA, Harrington, AM, Castro, J, et al. Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes. Gut 62 (2013), 1456–1465.
87. 87 Hughes, PA, Moretta, M, Lim, A, et al. Immune derived opioidergic inhibition of viscerosensory afferents is decreased in irritable bowel syndrome patients. Brain Behav Immun 42 (2014), 191–203.
88. 88 Marshall, JK, Thabane, M, Garg, AX, et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 20 (2004), 1317–1322.
89. 89 Vazquez-Roque, MI, Camilleri, M, Smyrk, T, et al. Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea. Am J Physiol Gastrointest Liver Physiol 303 (2012), G1262–G1269.
90. 90 Shulman, RJ, Jarrett, ME, Cain, KC, Broussard, EK, Heitkemper, MM, Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. J Gastroenterol 49 (2014), 1467–1476.
91. 91 Turcotte, JF, Kao, D, Mah, SJ, et al. Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). Gastrointest Endosc 77 (2013), 624–630.
92. 92 Bertiaux-Vandaële, N, Youmba, SB, Belmonte, L, et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol 106 (2011), 2165–2173.
93. 93 Wilcz-Villega, EM, McClean, S, O'Sullivan, MA, Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: implications for the mechanisms of barrier dysfunction in irritable bowel syndrome. Am J Gastroenterol 108 (2013), 1140–1151.
94. 94 Martínez, C, Lobo, B, Pigrau, M, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut 62 (2013), 1160–1168.
95. 95 Vivinus-Nébot, M, Dainese, R, Anty, R, et al. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol 107 (2012), 75–81.
96. 96 Fritscher-Ravens, A, Schuppan, D, Ellrichmann, M, et al. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology 147 (2014), 1012–1020.
97. 97 Talley, NJ, Fodor, AA, Bugs, stool, and the irritable bowel syndrome: too much is as bad as too little?. Gastroenterology 141 (2011), 1555–1559.
98. 98 Lundåsen, T, Gälman, C, Angelin, B, Rudling, M, Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 260 (2006), 530–536.
99. 99 Triantis, V, Saeland, E, Bijl, N, Oude-Elferink, RP, Jansen, PL, Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1. Hepatology 52 (2010), 656–666.
100. 100 Hofmann, AF, The syndrome of ileal disease and the broken enterohepatic circulation: cholerhetic enteropathy. Gastroenterology 52 (1967), 752–757.
101. 101 Thaysen, EH, Pedersen, L, Idiopathic bile acid catharsis. Gut 17 (1976), 965–970.
102. 102 Bajor, A, Tornblom, H, Rudling, M, Ung, KA, Simrén, M, Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut 64 (2015), 84–92.
103. 103 Aziz, I, Mumtaz, S, Bholah, H, Chowdhury, FU, Sanders, DS, Ford, AC, High prevalence of idiopathic bile acid diarrhea among patients with diarrhea-predominant irritable bowel syndrome based on Rome III criteria. Clin Gastroenterol Hepatol 13 (2015), 1650–1655.
104. 104 Shin, A, Camilleri, M, Vijayvargiya, P, et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 11 (2013), 1270–1275.
105. 105 Camilleri, M, Busciglio, I, Acosta, A, et al. Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea. Am J Gastroenterol 109 (2014), 1621–1630.
106. 106 Duboc, H, Rainteau, D, Rajca, S, et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 24 (2012), 513–520.
107. 107 Dior, M, Delagrèverie, H, Duboc, H, et al. Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. Neurogastroenterol Motil, 2016 published online April 5. http://dx.doi.org/10.1111/nmo.12829.
108. 108 Berger, M, Gray, JA, Roth, BL, The expanded biology of serotonin. Annu Rev Med 60 (2009), 355–366.
109. 109 Gershon, MD, Wade, PR, Kirchgessner, AL, Tamir, H, 5-HT receptor subtypes outside the central nervous system: roles in the physiology of the gut. Neuropsychopharmacology 3 (1990), 385–395.
110. 110 Gershon, MD, Tack, J, The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132 (2007), 397–414.
111. 111 Dunlop, SP, Jenkins, D, Neal, KR, Spiller, RC, Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 125 (2003), 1651–1659.
112. 112 Dunlop, SP, Coleman, NS, Blackshaw, E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 3 (2005), 349–357.
113. 113 Atkinson, W, Lockhart, S, Whorwell, PJ, Keevil, B, Houghton, LA, Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 130 (2006), 34–43.
114. 114 Foley, S, Garsed, K, Singh, G, et al. Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology 140 (2011), 1434–1443.
115. 115 Thijssen, AY, Mujagic, Z, Jonkers, DM, et al. Alterations in serotonin metabolism in the irritable bowel syndrome. Aliment Pharmacol Ther 43 (2016), 272–282.
116. 116 Zhang, ZF, Duan, ZJ, Wang, LX, Yang, D, Zhao, G, Zhang, L, The serotonin transporter gene polymorphism (5-HTTLPR) and irritable bowel syndrome: a meta-analysis of 25 studies. BMC Gastroenterol, 14, 2014, 23.
117. 117 Cremon, C, Carini, G, Wang, B, et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 106 (2011), 1290–1298.
118. 118 Barbaro, MR, Di Sabatino, A, Cremon, C, et al. Interferon-gamma is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism. Am J Physiol Gastrointest Liver Physiol 310 (2016), G439–G447.
119. 119 Keszthelyi, D, Troost, FJ, Jonkers, DM, et al. Visceral hypersensitivity in irritable bowel syndrome: evidence for involvement of serotonin metabolism—a preliminary study. Neurogastroenterol Motil 27 (2015), 1127–1137.
120. 120 Park, SH, Videlock, EJ, Shih, W, Presson, AP, Mayer, EA, Chang, L, Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity. Neurogastroenterol Motil 28 (2016), 1252–1260.
121. 121 Ford, AC, Quigley, EM, Lacy, BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 109 (2014), 1350–1365.
122. 122 Hall, GB, Kamath, MV, Collins, S, et al. Heightened central affective response to visceral sensations of pain and discomfort in IBS. Neurogastroenterol Motil 22 (2010), 276–280.
123. 123 Tillisch, K, Mayer, EA, Labus, JS, Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 140 (2011), 91–100.
124. 124 Hong, JY, Kilpatrick, LA, Labus, J, et al. Patients with chronic visceral pain show sex-related alterations in intrinsic oscillations of the resting brain. J Neurosci 33 (2013), 11994–12002.
125. 125 Ellingson, BM, Mayer, E, Harris, RJ, et al. Diffusion tensor imaging detects microstructural reorganization in the brain associated with chronic irritable bowel syndrome. Pain 154 (2013), 1528–1541.
126. 126 Jiang, Z, Dinov, ID, Labus, J, et al. Sex-related differences of cortical thickness in patients with chronic abdominal pain. PLoS One, 8, 2013, e73932.
127. 127 Piche, M, Chen, JI, Roy, M, Poitras, P, Bouin, M, Rainville, P, Thicker posterior insula is associated with disease duration in women with irritable bowel syndrome (IBS) whereas thicker orbitofrontal cortex predicts reduced pain inhibition in both IBS patients and controls. J Pain 14 (2013), 1217–1226.
128. 128 Elsenbruch, S, Rosenberger, C, Bingel, U, Forsting, M, Schedlowski, M, Gizewski, ER, Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. Gastroenterology 139 (2010), 1310–1319.
129. 129 Elsenbruch, S, Rosenberger, C, Enck, P, Forsting, M, Schedlowski, M, Gizewski, ER, Affective disturbances modulate the neural processing of visceral pain stimuli in irritable bowel syndrome: an fMRI study. Gut 59 (2010), 489–495.
130. 130 Larsson, MB, Tillisch, K, Craig, AD, et al. Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome. Gastroenterology 142 (2012), 463–472.
131. 131 Aizawa, E, Sato, Y, Kochiyama, T, et al. Altered cognitive function of prefrontal cortex during error feedback in patients with irritable bowel syndrome, based on fMRI and dynamic causal modeling. Gastroenterology 143 (2012), 1188–1198.
132. 132 Gupta, A, Kilpatrick, L, Labus, J, et al. Early adverse life events and resting state neural networks in patients with chronic abdominal pain: evidence for sex differences. Psychosom Med 76 (2014), 404–412.
133. 133 Gray, M, Chao, C-Y, Talley, NJ, Koloski, NA, Holtmann, G, In patients with Crohn's disease functional MRI reveals an alteration of amygdala function induced by anti-TNFα that is associated with positive self-attribution biases and reduced symptom response to a standardised nutrient challenge. Gastroenterology 150:suppl 1 (2016), S526–S527 (abstr).
134. 134 Suttor, VP, Prott, GM, Hansen, RD, Kellow, JE, Malcolm, A, Evidence for pelvic floor dyssynergia in patients with irritable bowel syndrome. Dis Colon Rectum 53 (2010), 156–160.
135. 135 Keely, S, Walker, MM, Marks, E, Talley, NJ, Immune dysregulation in the functional gastrointestinal disorders. Eur J Clin Invest 45 (2015), 1350–1359.